Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug‐Drug Interaction Risks

Understanding the potential for and minimizing the impact of drug-drug interactions (DDIs) is important to patient-centric pharmacotherapy. To aid drug developers and healthcare providers, the US Food and Drug Administration (FDA) maintains a list of substrates, inhibitors, and inducers for major cytochrome P450 (CYP) enzymes and transporters. Herein, we provide an overview of the list and opine on research of Cicali et al. on the classification of CYP2D6 inhibitors, as an illustration of collaborative opportunity for external stakeholders in maintaining the list.